Xalud Therapeutics, Inc.
- UEI
- LVJKCZJKEKV3
- CAGE
- 5MSF3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- xaludthera.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Proposal log no. 13210014 | Medical Command (Army) | $2,505,218 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| XT-203: a novel pain and substance abuse therapeutic | Defense Health Agency | $1,412,161 | |
| XT-101: a potent IL-10 based therapy for treating multiple sclerosis. | National Institutes of Health | $689,217 | |
| XT-101: a novel and potent non-opioid treatment for neuropathic pain | National Institutes of Health | $2,847,606 |
Quick answers
Is Xalud Therapeutics, Inc. registered in SAM.gov?
Xalud Therapeutics, Inc.'s SAM.gov registration expired on May 10, 2025.
What is Xalud Therapeutics, Inc.'s most recent federal award?
Xalud Therapeutics, Inc.'s most recent federal grant award is XT-203: a novel pain and substance abuse therapeutic (W81XWH1810804), from Defense Health Agency, on September 30, 2018.
On GovTribe
See Xalud Therapeutics, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors